NCT00531401View on ClinicalTrials.gov

Study of Salirasib to Treat Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Salirasib

600mg BID until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

10017

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Concordia Pharmaceuticals, Inc

INDUSTRY